#United States #Needham #MLAB Biosciences #Peter Kang #Kathryn Wagner

MLAB Biosciences Expands Scientific Advisory Board

In a significant move towards enhancing its research capabilities, MLAB Biosciences has appointed two prominent figures in neuromuscular medicine, Dr. Kathryn R. Wagner and Dr. Peter B. Kang, to its Scientific Advisory Board (SAB). This strategic addition aims to fortify the company’s focus on developing innovative therapies for neuromuscular diseases, especially in light of their promising lead program, MLAB-001.

A New Era of Expertise

MLAB Biosciences, based in Needham, Massachusetts, has garnered attention for its pioneering efforts in biotechnology, specifically targeting neuromuscular disorders. The appointments of Wagner and Kang are expected to significantly bolster the SAB alongside its Chair, Dr. Edward M. Kaye, who is already recognized for his contributions in this vital field. Together, they bring a wealth of knowledge and expertise that will guide the company's ambitious goals.

Dr. Kathryn R. Wagner

Dr. Wagner is well-known as a leading neuromuscular physician-scientist, currently serving as Professor Emerita of Neurology and Neuroscience at Johns Hopkins School of Medicine. Her extensive background includes previous roles as Vice President and Global Head of Neuromuscular Diseases at Roche, and she is a founding director of the Center for Genetic Muscle Disorders at Kennedy Krieger Institute. With her profound focus on translational research in conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), Dr. Wagner’s expertise will be invaluable in steering MLAB towards impactful clinical outcomes.

Dr. Peter B. Kang

Adding to the SAB, Dr. Kang currently holds the position of Professor and Vice Chair of Research in the Department of Neurology at the University of Minnesota, where he directs the Greg Marzolf Jr. Muscular Dystrophy Center. His leadership extends to roles such as President of the Child Neurology Society and Editorial responsibilities with Neurology® Genetics. Formerly, he held key positions at the University of Florida and Boston Children’s Hospital, establishing himself at the forefront of genetic discovery in neuromuscular disorders. His background in pediatric neurology and research will greatly enhance MLAB's clinical pathway.

A Vision for the Future

Yunxiang Zhu, the Chief Scientific Officer and Co-Founder of MLAB Biosciences, expressed enthusiasm regarding the new appointees. He stated, “Their complementary strengths in translational science, patient-facing neuromuscular care, and academic leadership reinforce Ed Kaye's industry leadership. Together, they position our SAB to guide MLAB-001 toward the clinic and support the development of a pipeline of transformative therapies.”

Dr. Wagner echoed this sentiment, remarking on MLAB's bold approach to muscle regeneration. “I am excited to help guide the translation of this innovative strategy into meaningful therapies for patients,” she stated. Dr. Kang also looks forward to contributing, emphasizing that MLAB's unique scientific approach could address urgent needs in DMD and other related neuromuscular diseases.

The MLAB-001 Therapeutic

Central to MLAB Biosciences' mission is its lead program, MLAB-001. This muscle-specific antibody-fusion protein is ingeniously crafted to activate the Notch signaling pathway, promoting muscle regeneration effectively. Notably, its design is dystrophin-mutation agnostic, which presents a potential therapeutic benefit for all DMD patients, marking a significant advancement in treatment options. This strategic design positions MLAB-001 as a promising choice in conjunction with existing therapies, offering hope where few options currently exist.

Conclusion

As MLAB Biosciences assembles a Scientific Advisory Board of unparalleled depth in academic medicine, translational research, and neuromuscular drug development, it sets the stage for groundbreaking advancements in therapeutic solutions. With the invaluable insights from Drs. Wagner, Kang, and Kaye, MLAB is well on its way to making a transformative impact in the field of neuromuscular diseases, ultimately striving for better health outcomes for patients worldwide.

About MLAB Biosciences: MLAB is a biotechnology company supported by ABio-X Holding, aimed at innovating therapeutic interventions for musculoskeletal conditions through disruptive technologies and cutting-edge science.